52 filings
Page 2 of 3
8-K
13albl 9nf
15 Jun 23
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
8:23am
8-K
ctpz wc156
8 Jun 23
Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
4:01pm
8-K
wul2mpve9syv
2 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:20pm
8-K
97vpzf
11 May 23
Femasys Inc. Announces Financial Results for the First Quarter Ended First Quarter 2023 Financial Results
4:11pm
8-K
kjcjnfg2tjx jbq
4 May 23
Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
4:01pm
8-K
5w005d92 evrmwy
20 Apr 23
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
9:41am
8-K
o7711aaj7bz37
18 Apr 23
Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
9:31am
8-K
h5d4h6 tb370i802
31 Mar 23
Disrupting Convention in Women’s Health Through Continuous Innovation March 2023 Corporate Presentation 1
5:03pm
8-K
pu1wl3rv4ao 7ss
30 Mar 23
Results of Operations and Financial Condition
8:05am
8-K
ue5f2f
13 Mar 23
Other Events
9:28am
8-K
l3wnzzs9zh8zhv31fz
21 Dec 22
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
4:01pm
8-K
m19mkweugcoy 1ke3
10 Nov 22
Femasys Inc. Announces Financial Results for the Third Quarter Ended Third Quarter and Recent Developments Related to Clinical Programs and Commercial Products
8:35am
8-K
x5m0zwdz
20 Oct 22
Disrupting Convention in Women’s Health Through Continuous Innovation October 2022 Corporate Presentation 1
8:34am
8-K
9y0lp
12 Oct 22
Femasys Inc. Announces the Appointment of Christine Thomas As Senior Vice President of Regulatory and Clinical Affairs
8:46am
8-K
uuk7xzgj
6 Oct 22
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
8:49am
8-K
7a9rdgs
29 Sep 22
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
8:41am
8-K
306u 2nlqqflew7
10 Aug 22
Femasys Inc. Announces Financial Results for the Second Quarter Ended Second Quarter and Recent Developments Related to Clinical Programs
4:06pm
8-K
2m0p66k
2 Aug 22
Disrupting Convention in Women’s Health Through Continuous Innovation August 2022 Corporate Presentation 1
5:08pm
8-K
cgevwxb57spnnx 4dw
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
hzhjd89l
11 May 22
Femasys Inc. Announces Financial Results for the First Quarter Ended Continued progress with FemaSeed and FemBloc biomedical product candidates in development
4:11pm